

SAMPLE REPORT ONLY

Civetta Therapeutics

Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.

Location:	Cambridge, Massachusetts, United States
Categories:	Biotechnology, Life Science, Therapeutics
Headquarters Regions:	Greater Boston Area, East Coast, New England
Founded Date:	2019
Founders:	Eric Fischer, William Sellers
Operating Status:	Active
Funding Status:	Early Stage Venture
Last Funding Type:	Series A
Number of Employees:	11-50
Also Known As:	Civetta
IPO Status:	Private
Company Type:	For Profit
Revenues:	\$0
Website:	www.civettatherapeutics.com/
LinkedIn:	https://www.linkedin.com/company/civetta-therapeutics

Employees (6)

1. Earl May, Vice President of Lead Discovery
2. Joseph Kelleher, Vice President of Biology
3. William Sellers, Co-Founder
4. Eric Fischer, Co-Founder
5. Andrew Cook, Vice President and Head of Chemistry
6. Bruce Goldsmith, Interim CEO

Funding Rounds

Civetta Therapeutics has raised a total of \$53M in funding over 1 round. This was a Series A round raised on Dec 4, 2019.

Investors

Civetta Therapeutics is funded by Deerfield Management.

Recent News and Activity

Dec 4, 2019, Civetta Therapeutics raised \$53,000,000 / Series A from Deerfield Management

Description:

Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains. The company leverages small molecule targeting of beta-propeller domains to develop important therapeutics for cancers and other diseases. It also develops a broad range of expertise in drugging the propeller domains, spanning from biochemistry to biology to medicinal chemistry

Propeller proteins are structural scaffolds that mediate protein-protein interactions of unique substrates. These proteins are found ubiquitously across cell types and can have diverse functional roles in the pathogenesis of cancer, neurodegeneration, metabolic disease, and other areas.

Their vision is to build a portfolio of therapeutics by integrating a broad range of expertise in drugging the propeller domains spanning from biochemistry to biology to medicinal chemistry. These efforts will support the creation of near term therapeutics and longer-term value in becoming a leader in this space.

Civetta Therapeutics was founded in 2019 and is based in Cambridge, Massachusetts, United States.